Clinical Trial Update: Evaluating the Efficacy and Safety of Fulvestrant Plus DNA Damage Repair Inhibitors After a CDK4/6 Inhibitor [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating the combination of fulvestrant with a DNA damage repair inhibitor in advanced breast cancer patients who previously recei…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• DNA damage repair inhibitor (DNA damage repair inhibitor)
• Faslodex (fulvestrant)

Snippet

Sponsor: Seoul National University Hospital | Conditions: Advanced Breast Cancer | Phase 2 | Status: RECRUITING